Our mission is to generate new therapies for cardiovascular-metabolic disorders, and reverse unfavorable aspects of aging.
- What's new -
Nakao M, Shimizu I*,**, Katsuumi G, Yoshida Y, Suda M, Hayashi Y, Ikegami R, Hsiao Yung Ting, Okuda S, Soga T, Minamino T**.
Empagliflozin Maintains Capillarization and Improves Cardiac Function in a Murine Model of Left Ventricular Pressure Overload.
Sci Rep 11, Article number: 18384 (2021). Co-first author, *corresponding
Graphical abstract of our findings.
(Fig. 4J; Sci Rep 11, Article number: 18384 (2021))
We found empagliflozin enhances capillarization in heart and ameliorate cardiac dysfunction upon left ventricle pressure overload.
Together with our previous studies in Nature 2007, J Clin Invest 2010, Cell Metab 2012, our studies indicate the critical role of maintaining capillaries in heart.
Professor Sakai Mashito in Nippon Medical School gave us a talk at MARS (Cardiovascular-Metabolism-Aging Research Seminar); ISHR U45-Satellite Symposium. Thank you Dr. Sakai!
José Javier Fuster Ortuño in CNIC gave us a talk at CREATE-International Symposium! Thank you Jose!!
(The Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Hematovascular Pathophysiology, Madrid, Spain)
Frontiers in Cardiovascular Medicine; IF 6.05! Awesome!!
Ippei Shimizu appointed as a leader of U45-ISHR Japanese section.
(International Society of Heart Research).
We moved to Juntendo University, Tokyo, Japan.
Winner; Yung Ting Hsiao; YIA competition for International Students, 84th Annual Scientific Meeting of Japanese Circulation Society 2021 (JCS2021)
Hsiao YT*, Shimizu I*,**, Wakasugi T, Jiao S, Watanabe T, Yoshida Y, Ikegami R, Hayashi Y, Suda M, Katsuumi G, Nakao M, Ozawa T, Kashimura T, Ozaki K, Hanawa H, Minamino T**. Cardiac Mitofusin-1 is Reduced in Non-responding Patients with Idiopathic Dilated Cardiomyopathy. Sci Rep. , Mar24; 11(1):6722, 2021. *Co-first author, **Co-corresponding author